Objective: The vast majority of pancreatic cancers occurs sporadically. The discovery of frequent variations in germline gene copy number can significantly influence the expression levels of genes that predispose to pancreatic adenocarcinoma. We prospectively investigated whether patients with sporadic pancreatic adenocarcinoma share specific gene copy number variations (CNVs) in their germline DNA. Patients and methods: DNA samples were analyzed from peripheral leukocytes from 72 patients with a diagnosis of sporadic pancreatic adenocarcinoma and from 60 controls using Affymetrix 500K array set. Multiplex ligation-dependent probe amplification (MLPA) assay was performed using a set of self-designed MLPA probes specific for seven target sequences. Results: We identified a CNV-containing DNA region associated with pancreatic cancer risk. This region shows a deletion of 1 allele in 36 of the 72 analyzed patients but in none of the controls. This region is of particular interest since it contains the YTHDC2 gene encoding for a putative DNA/RNA helicase, such protein being frequently involved in cancer susceptibility. Interestingly, 82.6% of Sicilian patients showed germline loss of one allele. Conclusions: Our results suggest that the YTHDC2 gene could be a potential candidate for pancreatic cancer susceptibility and a useful marker for early detection as well as for the development of possible new therapeutic strategies.
Introduction
Pancreatic cancer accounts for 3% of all new cases of cancer and it is the fourth leading cause of cancer death, with an overall 5-year survival rate of < 5%. This incidence has not changed in nearly 50 years [1] . Pancreatic cancer is one of the most lethal human cancers and its prognosis has not been improved despite advances in diagnostic and therapeutic strategies [2] . Environmental factors such as cigarette smoking [3] [4] [5] or diseases such as diabetes [6, 7] , obesity [8, 9] or chronic pancreatitis [10, 11] can predispose to pancreatic cancer [12] . Heritable genetic predisposition is also sometimes involved [13, 14] . The lifetime risk of pancreatic cancer is 4.7% for first-degree relatives of patients with pancreatic cancer and the familial risk of pancreatic cancer increases with each affected family member [15, 16] . Pancreatic cancer can also be inherited as part of a multi-cancer syndrome such as cancers associated with BRCA2 mutations [17, 18] , Peutz-Jeghers syndrome [19] , Fanconi anemia syndrome [20] and familial atypical multiple mole-melanoma syndrome [21] . In these cases, the family pedigree reveals the occurrence of other cancers such as breast or intestinal tumors, or melanomas, in addition to pancreatic tumors. However, most pancreatic cancers are sporadic. The molecular mechanism by which they occur involves the same alterations in somatic gene expression as in other cancers, which include KRAS2, BRCA2 and TP53 mutations, telomere shortening, p21 (WAF1/CIP1) and cyclin D1 upregulations, expression of proliferation antigens, and inactivation of p16 INK4 /CDKN2A and DPC4/SMAD4 [22] . However, the mechanisms that account for sporadic occurrence remain unknown. The discovery of frequent variations in gene copy number (CN) in germline DNA might further show how the sporadic occurrence of pancreatic cancer occurs [23] [24] [25] [26] . Such variations can significantly influence the expression levels of involved genes [27] and it is conceivable that some gene copy number variations (CNVs) lead to peculiar alterations of gene expression that predispose to pancreatic adenocarcinoma [28] .
We performed a high-resolution genomic microarray analysis on germline DNA of patients with sporadic pancreatic adenocarcinoma to determine the rate of de novo CNV and to identify common DNA regions containing pancreatic cancer-associated CNVs that are not detected in healthy individuals. Specific cancer-associated genes with aberrant CN could be useful biomarkers for the early detection and for the development of possible new therapeutic strategies.
In our study, we identified a CNV-including DNA region that contains the YTHDC2 gene. This gene maps on chromosome 5 (5q22.2) and encodes for a putative ATP-dependent RNA helicase involved in translation initiation. YTHDC2 expression was shown in tumor cell lines and TNF-a-treated hepatocytes. However, the function of YTHDC2 in the cancer cells and the mechanism by which the YTHDC2 gene is transcribed in these cells are largely unknown [29] . In a recent work, Tanabe et al. showed that YTHDC2 plays an important role in cancer cell growth, the activation/recruitment of ATF-2 and c-Jun to the YTHDC2 promoter region is necessary for the transcription of YTHDC2, and that histone deacetylase activity is required for the efficient expression of YTHDC2 in both hepatocyte and hepatocellular carcinoma cells [29] . Furthermore, rare mutations in the YTHDC2 gene have been identified in individuals with autism spectrum disorders [30] .
Patients and methods

Sample collection
Written informed consent was obtained from all participants. We prospectively collected 72 DNA samples from the peripheral leukocytes of 72 patients with a diagnosis of sporadic pancreatic adenocarcinoma. Patients with a familial pancreatic cancer history were excluded from the study. Diagnosis of adenocarcinoma was confirmed by histologic analysis. All clinical information for each enrolled patient was recorded anonymously and coded. All DNA samples were of sufficient quality to be genotyped. Patients were European (32 from Brussels, 23 from Palermo, 11 from Barcelona and 6 from Leipzig, as self-reported in the presence of the physician). Of these patients, 39 were men and 33 were women, with a mean age of 66 years. Sixty DNA samples from individuals of European origin were used as controls. We used the HapMap database as a reference [23] .
2.2 CNV analysis DNA was extracted from whole blood using the QIAamp mini kit (Qiagen, Chatsworth, CA, USA), according to the manufacturer's instructions. The DNA yields and purity were determined spectrophotometrically by measuring the absorbance of aliquots at 260 and 280 nm. DNA was prepared for microarray hybridization using the GeneChip Mapping Assay Protocol (Affymetrix, Inc., Santa Clara, CA, USA) as previously described by Pugh et al. [31] . The raw images were analyzed using the GeneChip Operating Software (GCOS Ver1.4.1) and GTYPE (Ver4.1) software (Affymetrix). We excluded samples with a genotype call rate < 93% (http://www.biostat.jhsph.edu/~iruczins/teaching/misc/gwas/ papers/affymetrix2006.pdf) [32, 33] . To assess CN alterations we used CNAT (Ver4.0.1) software.
We set the genomic smoothing at 0.01 Mb and kept default parameters for the other variables. CN estimates were obtained using data from 172 HapMap samples (available online) as a reference. Chromosome X was not analyzed to avoid gender-related complications [34] . Reproducibility of the method was assessed by analyzing six DNAs from patients with pancreatic adenocarcinoma in duplicate, the second analysis confirming > 96% of CNVs obtained in the first analysis.
Data analysis
Using SAS software and ad hoc programs, individual tables generated by CNAT (CNATv4.0.1) were merged and probes were ranked according to their CN value. Two lists containing the probes with CN gains (3 or 4 copies) or loss (1 or 0 copies) were generated. However, to avoid false-positive number variations due to random noise in signal intensity, we retained only the probes that showed the same condition, that is gain or loss, in all 72 patients. Selected probes were merged with their respective gene annotations and physical positions according to the NCBI human genome sequence using the NetAffx web server (Affymetrix).
Multiplex ligation-dependent probe amplification
Multiplex ligation-dependent probe amplification (MLPA) [35] was performed on genomic DNA isolated from peripheral blood leukocytes using an MRC Holland's EK1 kit, according to the manufacturer's protocol, using self-designed synthetic MLPA probes. The MLPA reaction was performed in five main steps: i) DNA denaturation and hybridization of MLPA probes; ii) ligation reaction; iii) polymerase chain reaction (PCR); iv) separation of amplification products by electrophoresis; and v) data analysis. Following MRC-Holland recommendations, we designed seven sets of synthetic MLPA probes (Invitrogen, Carlsbad, CA, USA) to detect deletions in several regions of YTHDC2 gene ( Table 1) . To test the quality of the 'home-made' probes and performed MLPA reactions, as well as facilitate data analysis, we used 'SALSA MLPA kit P200-A1 Reference probemix 1' (MRC-Holland) as a reference internal control (data not shown). Synthetic probe mix was obtained by combining 0.8 µl of each 1 µM oligo (halfprobe) solution in a final volume of 200 µl of Tris--EDTA. For each MLPA reaction, we used 1 µl P200 + 0.5 µl synthetic probe mix + 1.5 µl MLPA buffer. Ligation products were amplified by PCR. The PCR conditions were 30 sec at 95 C, 30 sec at 60 C and 1 min at 72 C for 35 cycles; 20 min at 72 C. The resulting amplification products (from 130 to 480 nt in length) were separated and analyzed by capillary electrophoresis using ABI 3100 Genetic Analyzer (Applied Biosystems). GeneMapper Ò v3.5 software (Applied Biosystems) was used to determine peak heights and areas, and fragment sizes in base pairs (bp). Specific peaks corresponding to each tested region of the YTHDC2 gene were identified according to their migration in relation to size standards.
Peak heights and areas of each fragment were compared to those of 10 non-pancreatic cancer control samples and potential heterozygous deletions were suspected when peak height and area differed by approximately 50%. Furthermore, duplicate assays were performed to check the accuracy of the MLPA analysis data.
Results
Germline DNA analysis reveals specific CNVs in patients with pancreatic adenocarcinoma
In this work, we used the Affymetrix platform to genotype 500,000 unique probes in patients with pancreatic adenocarcinoma to investigate whether patients shared specific CNVs associated with the disease that were not detected in individuals without pancreatic cancer. Several DNA regions that showed different CNV profiles in patients and controls were selected. One of these, where the CNV profile was associated with sporadic pancreatic cancer with high significance (p values from 2.25E-11 to 6.87E-08 depending on the probe set), was found particularly interesting. In this region, one allele was deleted in 36 (50%) of the 72 analyzed patients, but not in the controls. The deleted region is located on chromosome 5 (112,872,760 to 112,962,031) and its size ranges from 85,687 to 41,608 nt ( Table 2 ). This region contains the YTHDC2 gene (112,877,309 to 112,958,880, total size 81,571 bp). The smallest deletions detected in patients encompassed at least 51% of the YTHDC2 gene, including several (8) exons ( Figure 1) . Interestingly, 19 of 36 patients showing heterozygous deletion in the DNA region containing YTHDC2 are Sicilian (52.8%). Therefore, 82.6% (19 of 23) of patients from Palermo had a germline loss of one allele in that gene. Furthermore, very similar results were found when segmentation analysis was performed in parallel, using the Partek Genomics Suite (Partek GS) (data not shown).
3.2 YTHDC2 may be a potential susceptibility gene for sporadic pancreatic adenocarcinoma The YTHDC2 (YTH domain containing 2) gene encodes for a 1430-amino acid protein with a theoretical molecular weight of 160,248 Da. The YTHDC2 protein contains seven well-conserved domains, including an R3H domain (which binds to ssDNA or ssRNA in a sequence-specific manner), a DEAD-like helicase superfamily domain (with helicase activity), an ANK-repeat domain (which mediates protein--protein interactions), another DEAD-like helicase superfamily domain with helicase activity, a HA2 domain found in various helicases, potentially involved in nucleic acid binding, a DUF1605 domain systematically found toward the Cterminus of the DEAD box-containing helicases and a YTH domain, which likely modulates alternative splice site selection in a concentration-dependent manner. Although its function has not yet been studied, its primary structure strongly suggests that it is an ssRNA-or ssDNA-binding helicase. The fact that in Drosophila the maleless gene product, which has a similar organization (Figure 2) , is a well-established helicase supports this hypothesis [36, 37] . Therefore, YTHDC2 protein is expected to have several molecular functions such as ATP binding, ATP-dependent helicase activity, hydrolase activity, nucleic acid binding and nucleotide binding. Figure 3 shows some putative interactions of YTHDC2.
MLPA analysis
Because half of the patients with pancreatic adenocarcinoma showed a germline heterozygous deletion in a region of chromosome 5 containing YTHDC2, seven gene regions were selected for MLPA validation to confirm data previously obtained by genome-wide CNV analysis. An MLPA assay was performed in 36 patients showing loss of one allele, using a set of self-designed synthetic MLPA probes specific for seven target sequences of YTHDC2 ( Table 1) . We normalized the samples by using peak height and area values and comparing the patients with 10 healthy controls that had no CNVs (deletions or amplifications) in YTHDC2, as confirmed by a previous analysis (data not shown). Heterozygous deletions were detected when peak height and area of each fragment were reduced by approximately 50% with respect to controls (Figure 4) . MLPA analysis indicated that YTHDC2 target sequences showed a putative germline heterozygous deletion only in 10 of 36 (27.8%) patients with pancreatic adenocarcinoma, partially confirming the previously obtained CNV analysis data (Table S1 ). Interestingly, among these, six patients are from Palermo, in part confirming the relatively higher percentage of patients belonging to this geographical area showing germline loss of one allele of YTHDC2. 
Discussion
Pancreatic cancer is one of the most common fatal malignant tumors worldwide with poor prognosis and frequent resistance to conventional therapies such as radiotherapy or chemotherapy [38] [39] [40] . CNV has recently gained considerable interest as a source of genetic variation as it seems to play a role in phenotypic diversity and evolution [25] . Associations between CN changes and complex diseases were discovered in whole-genome association studies. Furthermore, genome analysis provided a powerful approach to test for evidence of genetic variations within and between geographical regions and local populations [41, 42] . In a recent work, Chen et al.
reported that whereas the overall CN variant frequencies are similar between populations, their distribution is highly specific to the population of origin [43] . DNA samples used in this study include those from groups of individuals from different geographical areas so as to facilitate detection of possible population-specific common variants. However, this approach involves that variants that are rare and populationrestricted could be not detected because the number of individuals examined in each population is small. The germline CNV identified in this study was found in 36 of the 72 -analyzed patients with sporadic pancreatic adenocarcinoma, but in none of the 60 controls, indicating that this DNA anomaly is frequent in patients and rare in non-affected people. If this alteration generates a functional defect involved in the occurrence of sporadic pancreatic cancer, its absence in half of the patients should be explained. At least two possibilities can be considered. The first is that other functional defects, other than a defect in YTHDC2 gene, can trigger pancreatic adenocarcinoma. Indeed, we found other CNVs associated with pancreatic cancer with a lower frequency that might account for such defects. The second possible explanation is technical. We cannot exclude the possibility that short DNA losses or other DNA anomalies involving this region were undetectable with our approach. These include inversions, insertions and more complex rearrangements, which are found in other patients with pancreatic cancer. Interestingly, our genome microarray analysis detected that 19 of 23 (82.6%) patients from Palermo (Italy) showed germline heterozygous deletion in the DNA region containing YTHDC2. MLPA analysis further confirmed that most of the patients showing loss of one allele in YTHDC2 (27.8%) belongs to geographical area of Palermo (Italy). Because CNVs may differ greatly among different populations, we hypothesize a putative population-specific CNV in this region. However, further investigations are needed to confirm this hypothesis. Therefore, we suggest that YTHDC2 could be a potential candidate for susceptibility to pancreatic cancer. To our knowledge, this is the first report that associates a particular CNV with susceptibility to a sporadic cancer. Interestingly, results from a microarray analysis on familial pancreatic cancer [44] showed that patients with a familial history of pancreatic cancer had a total of 56 unique germline genomic regions with CNVs that were not present in the controls, including 31 amplifications and 25 deletions. These patients did not show DNA MLPA-derived amplification products were separated by electrophoresis and peak patterns were generated from a control DNA sample (A) and a patient sample (B). Relative amounts of probe amplification products, compared to a control DNA sample, reflect the relative copy number of seven target sequences. The comparison between the peak heights showed a reduction by approximately 50% in patient sample with respect to control.
MLPA: Multiplex ligation-dependent probe amplification.
YTHDC2 in sporadic pancreatic cancer
Expert Opin. Ther. Targets (2014) 18 (8) anomalies in the YTHDC2 gene region, suggesting that familial and sporadic pancreatic cancers develop through different pathways. In addition, a truncating germline mutation in the PALB2 gene was found in several patients with familial pancreatic cancer. PALB2 protein is a binding partner for BRCA2. PALB2 mutations have previously been reported in patients with familial breast cancer, and PALB2 is now considered to be a susceptibility gene for pancreatic cancer [45] . An attractive hypothesis is that genomic alterations associated with inherited pancreatic cancer have sufficient penetrance to trigger the disease, whereas alterations associated with sporadic pancreatic cancer require the additional influence of environmental factors [22] . In 2009, Amundadottir et al. [46] identified an SNP that maps to the first intron of the ABO blood group gene, which is significantly associated with pancreatic cancer, suggesting that people with blood group O may have a lower risk than those with groups A or B. However, the involvement of this SNP in susceptibility to pancreatic cancer remains to be established. We cannot exclude the possibility that a specific CNV is also associated with other forms of cancer. Evaluating pancreatic specificity by repeating the analysis with a series of DNA samples from patients with other cancers was beyond the scope of this study. However, if cancer is the consequence of a given series of inherited genetic imbalances, the corresponding CNV should be found in a population of individuals chosen at random, in a proportion corresponding to cancer occurrence in humans (American Cancer Society 2007). We did not find the same proportion of CNV (~20%) in our control population, suggesting that there is no clear genetic predisposition to cancer in general, but that more specific genetic abnormalities predispose individuals to cancers of specific organs. The CNV identified in this study, associated with susceptibility to pancreatic adenocarcinoma, might be an example of such specificity.
The CNV selected in this study comprises at least 51% of the YTHDC2 gene, including several exons, indicating that one allele is inactivated in patients with sporadic pancreatic cancer. The YTHDC2 gene encodes for a putative helicase, well conserved in pluricellular eukaryotes, including early organisms. The YTHDC2 function has not yet been established, but several proteins with similar structures are DNA and/or RNA helicases. How the deletion of one YTHDC2 allele is a potential susceptibility factor for pancreatic adenocarcinoma also remains to be elucidated. However, activity loss of several helicases has been implicated in breast and prostate cancer susceptibility. Helicases are involved in DNA and RNA metabolism, including DNA repair and recombination, chromosomal stability, splicing and removal of proteins from RNA. Some may act as viral receptors, others may be involved in transcription regulation and some are involved in the initial steps of eukaryotic translational mechanism. Many functions are strongly associated with the cancer development.
Conclusions
This is a preliminary/pilot study performed on individuals from different geographical areas in order to identify new possible common variants in sporadic pancreatic adenocarcinoma. However, we are looking at expanding our sample size to carry out a research more extended and to further confirm obtained results. The CNV reported in this study may help increase our understanding of the physiopathology of pancreatic cancer because gene deletions generate imbalances in the corresponding mRNA and encoded protein levels. For genes and pathways critically dependent on a fixed amount of a functional product, it seems likely that CNVs could account for individual variations in disease susceptibility [47] . Also, the interaction between germline modifications and somatic mutations could influence the phenotype. For instance, the result of a somatic mutation occurring in a gene whose expression is restricted to a single allele would correspond to a knock-out. In conclusion, these data suggest that the occurrence of pancreatic cancer involves a combination of specific somatic mutations and germline alterations. Knowledge of the genes whose CN is altered in pancreatic cancer could be useful for identifying patients at high risk of developing this disease both for diagnosis and also to possibly reveal new gene targets for preventive or curative strategies.
